Login to Your Account



Genentech Surges On Avastin Survival Data In Breast Cancer

By Karen Pihl-Carey


Monday, April 18, 2005
As if the news for Avastin couldn't get any better, Genentech Inc.'s stock swelled another 18.3 percent following the release of positive survival data in a third indication, breast cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription